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INTRODUCTION  
As we know, CANCER CAN COAPTATE THE IMMUNE CONTROL. However, some medications can disrupt immunological checkpoints and 
''release'' anti-tumor immunity. This complex biological process still contains many MYSTERIES and is currently the subject of an intense 
study. By making the most of this, cancer immunotherapy could be a key part of the clinical management of cancer in a specific way: in 
cancer patients, THE CANCER IMMUNITY CYCLE DOES NOT PERFORM OPTIMALLY so the goal of cancer immunotherapy is to initiate itself 
– sustaining cycle of cancer immunity enabling it to amplify, propagate and generate unrestrained autoimmune inflammatory responses 
to overcome the negative feedback mechanisms of cancer; also, important inflection points in the history of cancer therapy: durable 
monotherapy responses are being reported (in different human cancers with several different ages), new drugs and implement clinical 
strategies are indicated in melanoma (a disease thought to be atypically immunogenic) and immunology therapy of cancer could report 
safety and more manageable profiles tan traditional cancer therapies (they act specifically). A successful approach will be to find a 
common rate – limiting step in the TUMOR MICRO-ENVIRONMENT so that we can act selectively targeting it in any given patient (because 
amplifying the entire cycle may provide anticancer activity but also could damage normal cells and tissues, as chemotherapy).  
OBJECTIVE 
Our main objective is to evaluate the current status of anti-tumor immunotherapy. To do this, we will expose the most promising lines of 
research and cutting – edge treatments; to be able to conclude whether, currently (or in the future), we can contemplate immunotherapy 
as a viable treatment option.  
  
MATERIAL AND METHODS 
The conduction of this narrative review, will be based on the conference about cancer immunotherapy ‘’Medicina de Precisión e 
Inmunoterapia: retos y oportunidades para el tratamiento del cáncer’’ Dr. Mariano Barbacid. Also, we contacted Pedro Romero, who 
works at Ludwig Cancer Research at University of Lausanne, 1066 Epalinges, (Switzerland); and who recommended us the articles written 
on ‘’references’’ (key words: cancer, immunotherapy and review; 5 years) which have been used and the publications quoted in those 
articles.  
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RESULTS AND DISCUSSION 
 
CANCER REJECTION IS A 7-STEP PROCESS (figure 1). This cycle 
presents the anti-tumor response and, by dissecting it, we will 
know the potential points of attack in tumor immunotherapy.  
 
So, WHY DOES THE IMMUNE SYSTEM FAIL? 
 
As Chen & Mellman (2013) show in their article, the 
manipulation of the second activating signal could abrogate 
anti-cancer immune reactions (who apparently blocks B7 
expression and over-express CTLA-4). The scientific community 
soon realized that this swarm of stimulatory and inhibitory 
molecules inter-playing in the anti-tumor immune response 
could be able manipulated to improve such response. This 
approach has been termed IMMUNE CHECKPOINT BLOCKADE, 
in other words, “molecules than can be blocked to free the 
immune system to destroy tumor cells” (figure 2).  
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CONCLUSIONS 
 
Cancer can avoid the IS and the NeoAg created by the tumors cells are involved in this scape 
(although AutoAg can also be a selective target) and they have different expression patterns, 
signaling pathways, mechanisms of action... So, IMMUNOSUPPRESSION is the natural history of 
cancer and multiple mechanisms are known that may work together or in parallel; consequently, 
there is a need to pursue other potential agents (vaccines, intratumoral injections of immune 
activators, agonists of co-stimulatory receptors...). 
 
What is more, is reasonable to suspect that immunotherapy approaches from vaccines would be 
more effective when given in combination with, for example, a PD1-inhibitor. Subsequently, 
combination with agents, which must act in a SYNERGY WAY and that will enhance Tcell 
trafficking and infiltration into the tumor should be explored. 
 
 
 
 
 
CHIMERIC ANTIGEN RECEPTOR T CELLS (CARTS) 
Many tumor cells do not express HLA molecules, hence T cells 
cannot recognize them (figure 3). CAR T-cell therapy employs 
gene transfer techniques to reprogram endogenous T cells to 
target a specific tumor antigen. Patients typically receive 
chemotherapy, figure 4, the goal is to INDUCE 
LYMPHODEPLETION and thereby ENHANCE CAR T-CELL 
EXPANSION and persistence in vivo, lymphodepletion may 
have the additional benefit of tumor cytoreduction, which can 
potentially improve CAR T-cell treatment efficacy and minimize 
toxicity.  
MONOCLONAL ANTIBODIES 
Tremelimumab is a fully human 
IgG2 anti CTLA-4. It posed 
hopes in early melanoma. 
Ipilimumab is a fully human 
IgG1 anti CTLA-4.  Phase III trials 
showing improved survival so it 
was approved in 2011 in USA 
and Europe for the treatment 
of unresectable melanoma and 
a meta-analysis showed 
extended survival in 20% of 
patients, reaching 10 years in 
some cases.  
Nivolumab is a fully human 
IgG4 anti PD-1, and it showed 
good responses in human 
melanoma, kidney and rectal 
cancers.  
The lack of CD28 activation 
by binding CTLA-4 is a 
physiological phenomenon 
since it reacts with B7 with 
much higher affinity than 
CD28. So it interrupts the 
second activating signal, and 
T cells enter in a state of 
ANERGY. 
 
PD-1 has a role in 
controlling the 
SUPPRESSIVE FUNCTION of 
Treg playing a role in T cell 
recognition of antigens 
presented to T cells in 
secondary lymphoid organs.  
 
CANCER VACCINES 
 
Cancer vaccines seek to target a tumor-specific antigen and 
distinct from self-proteins. Tumor antigens have been divided 
into two categories: shared tumor antigens (expressed by many 
tumors) and UNIQUE TUMOR ANTIGENS (resulting from 
mutations induced through physical or chemical carcinogens, so 
they are expressed only by individual tumors). One approach 
could be vaccines containing whole tumor cells, but these 
vaccines have been less effective. Defined tumor antigens 
decrease the risk of autoimmunity, but tumors can evade 
destruction through antigen loss variance. A process called 
‘’epitope spreading’’ or ‘’provoked immunity’’ may mitigate this 
weakness. 
However, IMMUNE – RELATED TOXICITIES were also enhanced in their magnitude, 
frequency and onset (of course, increased activity due to combinations means also 
synergistic toxicity), but therapeutic targets that play an important role in mediating 
immune homeostasis and preventing autoimmunity must be selected.    
 
The development of an effective cancer immunotherapy requires an INTERNATIONAL 
AND MULTIDISCIPLINARY APPROACH due to its enormous complexity. Taking 
advantage of those complex discoveries and technological advances, we must DECODE 
THE HUMAN IMMUNE SYSTEM so cancer could be conquered.  
 
